Fasenra pen 30 MG/mlml
Ended Awarded Last action
- Contract number
- SPE2DR26FKKJ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,494
Award facts
- Contract value 100% obligated
- $2,493.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The award, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group will perform the work at its Park Ridge facility and serve as the sole contractor with no identified subcontractors on this delivery order.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded in November 2025 with a $500 million ceiling and extends through December 31, 2036. The PPV-G GEN V program, part of a broader $30.3 billion DLA acquisition strategy, establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. The vendor's recent substantial contracting activity and diverse product portfolio, which includes specialty pharmaceuticals, biologics, and routine medications, demonstrates its capability to fulfill specialized pharmaceutical requirements across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FKKJ8?
SPE2DR26FKKJ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FKKJ8 worth?
The government has obligated $2,494 on SPE2DR26FKKJ8.
Is contract SPE2DR26FKKJ8 an order under another contract?
Yes. SPE2DR26FKKJ8 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKJ8 competed?
The extent of competition for SPE2DR26FKKJ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award